Andrew M Blumenfeld

This inventor holds 28 USPTO granted patents and 30 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Botulinum Toxin Treatments. Top assignees: Allergan, Inc., Aeon Biopharma, Inc., Other. Active years: 2010-2023.

USPTO Granted Patents = 28 (Patent Applications = 30)

% Patents Active = 50.0

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 14)

Average Co-Inventor Count = 1.3

ph-index = 12

Forward Citations = 340(Granted Patents)

Location History:

San Diego, CA (US) (2014)
Del Mar, CA (US) (2010 - 2023)

Company Filing History:

2 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2023

Loading Chart...

Areas of Expertise:

Botulinum Toxin

Headache Treatment

Psychological Trauma

Neurological Disorders

Anxiety Disorders

Depression Treatment

Suture Line Administration

Targeted Delivery

Trigeminal Autonomic Cephalgias

Vascular Conditions

Injection Paradigm

Neuropsychiatric Disorders

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11826405 - Neurotoxin compositions for use in treating headache (2023-11-28),

2. 11077174 - Treatment of psychological trauma (2021-08-03),

3. 10874722 - Suture line administration technique using botulinum toxins (2020-12-29),

4. 10729751 - Injection paradigm for administration of botulinum toxins (2020-08-04),

5. 10456455 - Treatment of psychological trauma (2019-10-29),

6. 10220079 - Suture line administration technique using botulinum toxins (2019-03-05),

7. 10111938 - Injection paradigm for administration of botulinum toxins (2018-10-30),

8. 10064921 - Botulinum toxin treatments of neurological and neuropsychiatric disorders (2018-09-04),

9. 9827297 - Suture line administration technique using botulinum toxins (2017-11-28),

10. 9764009 - Treatment of psychological trauma (2017-09-19),

11. 9248168 - Suture line administration technique using botulinum toxins (2016-02-02),

12. 9238061 - Botulinum toxin treatment of anxiety and bipolar disorders (2016-01-19),

13. 8992941 - Method for treatment of esophageal spasm (2015-03-31),

14. 8846622 - Targeted delivery of botulinum toxin to the sphenopalatine ganglion (2014-09-30),

15. 8734810 - Botulinum toxin treatments of neurological and neuropsychiatric disorders (2014-05-27),

Title: Andrew M. Blumenfeld: Innovator in Neurotoxin Therapies

Introduction

Andrew M. Blumenfeld, based in Del Mar, California, is a prolific inventor holding 28 patents. His groundbreaking work primarily focuses on neurotoxin compositions and their applications in medical treatments, particularly for headaches and psychological trauma.

Latest Patents

Among his latest patents are innovative compositions aimed at addressing significant health issues. The first patent, "Neurotoxin compositions for use in treating headache," outlines novel methods and formulations for alleviating headache pain. Another significant contribution is titled "Treatment of psychological trauma," which discloses methods involving botulinum toxins and targeted exocytosis modulators to address psychological trauma in individuals, showcasing his focus on leveraging biotechnology for therapeutic advancements.

Career Highlights

Andrew's extensive career includes impactful tenures at renowned companies, including Allergan, Inc. His commitment to innovation in the medical field has led to numerous advancements in treatment methodologies that have the potential to improve countless lives.

Collaborations

Throughout his career, Andrew has collaborated with esteemed colleagues such as Mitchell F. Brin and Franklin D. Gaylis. These partnerships have undoubtedly enhanced the depth and breadth of his research and patents, driving forward the field of neurotoxicology.

Conclusion

Andrew M. Blumenfeld stands out as a significant figure in the world of medical innovation. With a robust portfolio of patents and strategic collaborations, he continues to make remarkable contributions that enhance our understanding and treatment of neurological and psychological conditions. His work exemplifies the transformative power of innovation in medicine.